278 related articles for article (PubMed ID: 8794983)
21. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis.
Hönigsmann H; Jaschke E; Gschnait F; Brenner W; Fritsch P; Wolff K
Br J Dermatol; 1979 Oct; 101(4):369-78. PubMed ID: 508604
[TBL] [Abstract][Full Text] [Related]
22. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison of 8-methoxypsoralen and 5-methoxypsoralen.
Berg M; Ros AM
Photodermatol Photoimmunol Photomed; 1994 Oct; 10(5):217-20. PubMed ID: 7880762
[TBL] [Abstract][Full Text] [Related]
23. PAMAM dendrimers as solubilizers and hosts for 8-methoxypsoralene enabling transdermal diffusion of the guest.
Borowska K; Laskowska B; Magoń A; Mysliwiec B; Pyda M; Wołowiec S
Int J Pharm; 2010 Oct; 398(1-2):185-9. PubMed ID: 20655371
[TBL] [Abstract][Full Text] [Related]
24. Model analysis of flux enhancement across hairless mouse skin induced by chemical permeation enhancers.
He N; Warner KS; Higuchi WI; Li SK
Int J Pharm; 2005 Jun; 297(1-2):9-21. PubMed ID: 15907593
[TBL] [Abstract][Full Text] [Related]
25. Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
Shephard SE; Panizzon RG
Dermatology; 1999; 199(2):106-12. PubMed ID: 10559574
[TBL] [Abstract][Full Text] [Related]
26. Spectrofluorimetric determination of 5-methoxypsoralen pharmacokinetic in patients' serum.
Saïd A; Makki S; Muret P; Toubin G; Humbert P; Millet J
Exp Dermatol; 1997 Apr; 6(2):57-63. PubMed ID: 9209885
[TBL] [Abstract][Full Text] [Related]
27. In vitro percutaneous absorption of arildone, a highly lipophilic drug, and the apparent no-effect of the penetration enhancer Azone in excised human skin.
Baker EJ; Hadgraft J
Pharm Res; 1995 Jul; 12(7):993-7. PubMed ID: 7494819
[TBL] [Abstract][Full Text] [Related]
28. Transdermal delivery of antiparkinsonian agent, benztropine. I. Effect of vehicles on skin permeation.
Gorukanti SR; Li L; Kim KH
Int J Pharm; 1999 Dec; 192(2):159-72. PubMed ID: 10567747
[TBL] [Abstract][Full Text] [Related]
29. Microemulsions for topical delivery of 8-methoxsalen.
Baroli B; López-Quintela MA; Delgado-Charro MB; Fadda AM; Blanco-Méndez J
J Control Release; 2000 Oct; 69(1):209-18. PubMed ID: 11018558
[TBL] [Abstract][Full Text] [Related]
30. Plasma and skin concentration of 5-methoxypsoralen in psoriatic patients after oral administration.
Zucchi A; Raho E; Marconi B; Nicoli S; Santini M; Allegra F; Colombo P; Bettini R; Santi P
J Invest Dermatol; 2001 Aug; 117(2):379-82. PubMed ID: 11511320
[TBL] [Abstract][Full Text] [Related]
31. DNA in psoriatic epidermis.
Sondergaard J; Lerche A; Bohr V; Leik V; Wadskov S
Acta Derm Venereol Suppl (Stockh); 1979; 87():59-63. PubMed ID: 294785
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis.
Shephard SE; Nestle FO; Panizzon R
Photodermatol Photoimmunol Photomed; 1999 Apr; 15(2):64-74. PubMed ID: 10321518
[TBL] [Abstract][Full Text] [Related]
33. Plasma levels of 8-methoxypsoralen following PUVA-bath photochemotherapy.
von Kobyletzki G; Hoffmann K; Kerscher M; Altmeyer P
Photodermatol Photoimmunol Photomed; 1998; 14(3-4):136-8. PubMed ID: 9779504
[TBL] [Abstract][Full Text] [Related]
34. Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
Nimkulrat P; Leenutaphong V; Sudtim S
J Med Assoc Thai; 2005 Oct; 88(10):1406-11. PubMed ID: 16519387
[TBL] [Abstract][Full Text] [Related]
35. 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
Tanew A; Ortel B; Rappersberger K; Hönigsmann H
J Am Acad Dermatol; 1988 Feb; 18(2 Pt 1):333-8. PubMed ID: 3279089
[TBL] [Abstract][Full Text] [Related]
36. Randomized double-blind comparative study of 8-methoxypsoralen bath plus UV-A treatment regimens.
Berroeta L; Man I; Dawe RS; Ferguson J; Ibbotson SH
Actas Dermosifiliogr; 2010 Oct; 101(8):729-30. PubMed ID: 20965019
[No Abstract] [Full Text] [Related]
37. Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
Studer-Sachsenberg EM; Piletta PA; Fathi M; Saurat JH; Salomon D
Dermatology; 1997; 195(1):81-3. PubMed ID: 9267751
[TBL] [Abstract][Full Text] [Related]
38. Treatment of psoriasis with polyethylene sheet bath PUVA.
Streit V; Wiedow O; Christophers E
J Am Acad Dermatol; 1996 Aug; 35(2 Pt 1):208-10. PubMed ID: 8708022
[TBL] [Abstract][Full Text] [Related]
39. Determination of the effect of lipophilicity on the in vitro permeability and tissue reservoir characteristics of topically applied solutes in human skin layers.
Cross SE; Magnusson BM; Winckle G; Anissimov Y; Roberts MS
J Invest Dermatol; 2003 May; 120(5):759-64. PubMed ID: 12713577
[TBL] [Abstract][Full Text] [Related]
40. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
